Search
-
[Webinar] KEYS - The Perils of Perception: Facts vs Fiction?
In this month’s episode of KEYS, we’ll be reviewing the dynamics of today’s perils of perception, discussing what it tells us about our world and considering how businesses can best respond.
-
11th wave of the Future Risks Barometer: In a world in polycrisis, never has the feeling of vulnerability been so strong
Ipsos and AXA publish today the 11th wave of the Future risks report. Conducted among a sample of 19,000 people representative of the national populations within 15 countries in the world and +3,000 risk experts within 50 countries, this study measures and classifies the levels of fear but also the feeling of vulnerability in the face of 25 different life risks.
-
More than one in two feel their country needs to do more on its infrastructure needs
The 2024 Global Infrastructure Report from Ipsos and the Global Infrastructure Investor Association (GIIA).
-
Conversations with AI Part VI: AI-powered moderator bots: Enhancing empathy or eroding connection?
In the sixth white paper in our Ipsos Views Conversations with AI series, we explore the role of a Moderator Bot powered by generative AI within qualitative research.
-
Ipsos World Mental Health Day Report
Younger people (particularly young women) are the most likely to feel depressed and take time off work due to stress according to an Ipsos report for World Mental Health Day 2024
-
[Webinar] Gen-AI-Powered Persona Bots: Bringing Healthcare Segmentations to Life
Watch Ipsos’ webinar, "GenAI-Powered Persona Bots: Bringing Healthcare Segmentations to Life
-
Ipsos Update - October 2024
Trends, News, Ageing … Ipsos Update explores the latest and research & thinking on key topics from Ipsos teams around the world.
-
What Worries the World – September 2024
Conducted monthly in 29 countries among 20,000 adults for over a decade, the Ipsos What Worries the World study offers an exceptional snapshot of world opinion on pressing global issues.
-
Predicting Opportunity in Emerging Therapies
The advent of groundbreaking therapies in the metabolic sector, including GLP-1, offers substantial opportunities for pharmaceutical companies, yet accurately estimating the size of these emerging markets, marked by significant unmet clinical needs, presents distinct challenges.